Alex I.
- Country
- The Netherlands
- Department
- Medical Oncology / Oncology center Deventer
Research Overview
- A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled by H1-antihistamines followed by an optional open-label extension for up to another 3 years and an optional safety long-term treatment-free follow-up period for up to an additional 3 years.
- Evaluation of Hepatic Arterial Infusion of Floxuridine with Systemic Therapy in Unresectable Colorectal Liver Metastases: A Randomized Controlled Trial
- Phase II Multicenter Randomized Trial of Neoadjuvant Chemotherapy and Chemoradiotherapy Regimens in Resectable Gastric Adenocarcinoma: Docetaxel, Capecitabine, Paclitaxel, Oxaliplatin, Carboplatin
Data & Insights
Has run more than one trial at 66 of 108 partner sites.
Specializations
Cardiovascular Disease and Metabolic Disorders
This investigator demonstrates extensive involvement in cardiovascular research, with particular emphasis on atherosclerotic cardiovascular disease and its associated risk factors. A significant portion of the research portfolio addresses elevated lipoprotein(a) and low-density lipoprotein cholesterol management through novel therapeutic interventions. The investigator participates in studies evaluating lipid-lowering therapies in patients with established cardiovascular disease, including those with type 2 diabetes and metabolic syndrome.
- Heart failure management and left ventricular dysfunction
- Myocardial infarction secondary prevention
- Atrial fibrillation and rhythm control strategies
- Peripheral arterial disease interventions
- Stroke prevention and anticoagulation therapy
The research extends to investigating PCSK9 inhibitors, CETP inhibitors, and antisense oligonucleotides targeting lipid metabolism. Studies focus on reducing major adverse cardiovascular events through innovative pharmacological approaches, including combination therapies with SGLT2 inhibitors and aldosterone synthase inhibition in chronic heart failure populations.
Oncology and Solid Tumors
The investigator maintains an active research presence in medical oncology, with concentrated efforts in gastrointestinal malignancies and breast cancer. Studies encompass metastatic colorectal cancer, including investigations of hepatic arterial infusion chemotherapy for colorectal liver metastases. The research portfolio includes work on rectal cancer, examining organ-preserving strategies through neoadjuvant chemoradiotherapy and transanal microsurgery approaches.
- HER2-positive breast cancer and dual HER2 blockade
- Triple-negative breast cancer biomarker development
- Hormone receptor-positive advanced breast cancer with CDK4/6 inhibitors
- Pancreatic adenocarcinoma perioperative strategies
- HER2-positive esophageal adenocarcinoma
The investigator contributes to precision oncology initiatives, including genomically-guided treatment selection for advanced solid tumors. Research activities involve evaluation of immune checkpoint inhibitors, particularly in non-small cell lung cancer and urothelial carcinoma, with focus on dose optimization and treatment duration strategies.
Hematologic Malignancies
This investigator participates in clinical research addressing lymphoproliferative disorders and plasma cell dyscrasias. The research encompasses advanced stage Hodgkin lymphoma, utilizing FDG-PET response-adapted therapy with brentuximab vedotin-containing regimens. Studies investigate novel therapeutic combinations in relapsed and refractory follicular lymphoma, incorporating bispecific antibodies with immunomodulatory agents.
- Multiple myeloma maintenance therapy strategies
- Anti-CD38 monoclonal antibody combinations
- Treatment-free interval approaches in newly diagnosed disease
- T-cell prolymphocytic leukemia targeted therapies
The investigator explores lenalidomide-based regimens and evaluates continuous versus intermittent treatment paradigms in multiple myeloma, assessing both efficacy and quality of life outcomes in patients achieving disease control.
Genitourinary Oncology
The research portfolio includes substantial work in metastatic castration-resistant prostate cancer, evaluating combinations of taxane chemotherapy with androgen receptor pathway inhibitors and radium-223. The investigator participates in studies examining drug-drug interactions between enzalutamide and commonly prescribed medications, including direct oral anticoagulants and opioid analgesics, addressing clinically relevant pharmacokinetic questions.
- Muscle-invasive bladder cancer systemic therapies
- Urothelial carcinoma maintenance strategies
- KRAS G12C-mutant non-squamous NSCLC
Additional research focuses on vulvar high-grade squamous intraepithelial lesions, investigating HPV vaccination as adjuvant therapy following surgical treatment to prevent disease recurrence.
Respiratory Medicine and Autoimmune Disorders
The investigator contributes to research in severe eosinophilic asthma, evaluating extended-interval dosing of anti-IL-5 pathway biologics and comparing efficacy of different type 2 inflammation inhibitors. Studies address chronic obstructive pulmonary disease with type 2 inflammation, exploring novel therapeutic approaches in this patient population.
- Relapsing multiple sclerosis anti-CD20 therapy
- Steroid-sensitive idiopathic nephrotic syndrome in pediatrics
- Polycystic ovary syndrome reproductive interventions
- Acute respiratory tract infections in hospitalized patients
Research activities extend to neonatal hypoxic-ischemic encephalopathy, investigating neuroprotective strategies with allopurinol as adjunct to therapeutic hypothermia. The investigator also participates in studies evaluating rituximab as an alternative to ocrelizumab in relapsing multiple sclerosis, addressing treatment accessibility and comparative effectiveness.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.